Almirall S.A., a global pharmaceutical company specialising in medical dermatology, announced a recognition by the CDP for its sustainability programme and carbon footprint management.
This recognition is the result of Almirall’s commitment to address climate change through actions focused on protecting the planet and promoting emission reduction initiatives throughout the entire value chain.
CDP, a not-for-profit charity, has the goal to guide companies and governments to reduce their greenhouse gas emissions, safeguard water resources and protect forests.
It independently evaluates data regarding environmental impact, risks and opportunities and is recognised as gold standard of environmental reporting.
“Achieving this recognition for our contributions to mitigating climate change is a testament to our commitment to sustainability throughout our operations and value chain.
As a healthcare company with a long-term view of our impact on people and societies, our contributions to creating a more sustainable future are at the heart of our business plan and actions,” commented Carlos Gallardo, Almirall’s CEO.
The Science-Based Targets initiative (SBTi) validated Almirall's targets to achieve net zero greenhouse gas (GHG) emissions across the value chain by 2050, under the "Net-Zero Standard".
This means an effective reduction of 50% of its absolute GHG emissions from own sources and purchased electricity and indirect emissions produced in the value chain by 28% by 2030 compared to 2019.